An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational
- Sponsors Menlo Therapeutics
- 30 May 2018 Status changed from planning to recruiting.
- 04 Apr 2018 New trial record
- 28 Mar 2018 According to a Menlo Therapeutics Inc media release, the company expects to start this trial in the second quarter of 2018.